Effectiveness of First‐Line Treatment With Recombinant Interleukin‐1 Receptor Antagonist in Steroid‐Naive Patients With New‐Onset Systemic Juvenile Idiopathic Arthritis: Results of a Prospective Cohort Study

Arthritis and Rheumatology - Tập 66 Số 4 - Trang 1034-1043 - 2014
Sebastiaan J. Vastert1, Wilco de Jager1, Bo Jan Noordman1, Dirk Holzinger2, Wietse Kuis1, Berent Prakken1, Nico Wulffraat1
1University Medical Centre Utrecht, Utrecht, the Netherlands
2University Children's Hospital Muenster and University of Muenster Muenster Germany

Tóm tắt

ObjectiveTo conduct a prospective cohort study using anakinra, a recombinant IL‐1 receptor antagonist (IL‐1Ra), as first‐line therapy in patients with new‐onset systemic juvenile idiopathic arthritis (JIA).MethodsTherapy with recombinant IL‐1Ra (2 mg/kg) was initiated in 20 patients who fulfilled the International League of Associations for Rheumatology criteria for systemic JIA, before systemic steroid treatment was administered. Patients were monitored clinically and immunologically. The protocol contained a stop strategy for patients who met at least the adapted American College of Rheumatology 90% criteria for improvement in JIA (ACR Pediatric 90 [ACR Pedi 90]) after 3 months.ResultsWe included consecutive patients with new‐onset systemic JIA. The mean followup period was 32 months (range 12–54 months). At the 3‐month time point, 85% of the patients showed an adapted ACR Pedi 90 response or had inactive disease; 75% of the patients achieved this response while receiving recombinant IL‐1Ra alone. After 1 year, 17 of the 20 patients met the criteria for clinically inactive disease, and 13 of these patients met these criteria while receiving monotherapy with recombinant IL‐1Ra. However, because of persistent disease activity, 7 of the 20 patients required additional therapy besides recombinant IL‐1Ra. According to our stop strategy, 73% of patients with at least an adapted ACR Pedi 90 response at 3 months could stop recombinant IL‐1Ra treatment within 1 year. After 2 years, 12 (86%) of 14 patients met the criteria for disease remission, either while receiving (n = 4) or not receiving (n = 8) medication. After 3 years, 10 (91%) of 11 patients met the criteria for disease remission, either while receiving (n = 2) or not receiving (n = 8) medication.ConclusionThis is the first prospective study in which recombinant IL‐1Ra was used as first‐line therapy in patients with systemic JIA. We observed excellent responses in nearly all patients within 3 months. In the majority of responding patients, treatment with recombinant IL‐1Ra could be stopped within 1 year, with remission being preserved during followup. In approximately one‐third of patients, concomitant therapy was required for maintenance of clinical response.

Từ khóa


Tài liệu tham khảo

10.1038/ncprheum0084

10.1016/S0140-6736(11)60244-4

10.1093/rheumatology/kem271

10.1093/rheumatology/keh710

10.1016/j.berh.2009.08.003

10.1002/art.20198

10.1084/jem.20050473

10.1056/NEJMoa1112802

10.1002/art.23437

10.1016/j.autrev.2012.07.022

10.1038/nrrheum.2011.68

10.1056/NEJMoa1205099

10.1002/art.1780340912

10.1172/JCI117206

10.1136/ard.2006.061853

10.1002/art.11177

10.1002/art.24349

10.1093/rheumatology/keg074

10.1186/ar1453

10.1067/mpd.2003.110

10.1002/art.24750

10.1016/S0022-3476(96)70140-3

10.1097/00002281-200209000-00012

10.1093/rheumatology/kep418

10.1002/art.23734

10.1136/ard.2003.014886

10.1093/rheumatology/kes019

10.1001/jama.2011.1671

10.1136/annrheumdis-2011-201060

10.1136/ard.2007.076034

10.1136/ard.2010.134254

10.1517/14712598.2010.532785

10.1002/art.30128

10.1002/acr.20460

Petty RE, 2004, International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001, J Rheumatol, 31, 390

10.1002/art.1780400703

Wallace CA, 2004, Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis, J Rheumatol, 31, 2290

Wallace CA, 2006, Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis, J Rheumatol, 33, 789

10.1007/978-1-60327-527-9_9

10.1002/art.20631

10.1002/acr.21889

10.1002/art.33342

10.1136/annrheumdis-2011-200598

10.1007/s10067-006-0474-0

10.1093/rheumatology/keq133

10.1016/j.cyto.2012.11.025

Lomater C, 2000, Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years, J Rheumatol, 27, 491

10.1002/1529-0131(200011)43:11<2402::AID-ANR5>3.0.CO;2-C

Thông tin
Thông tin xuất bản

Arthritis and Rheumatology

Tập 66 Số 4

1034-1043

Thông tin tác giả